Cisplatin neuropathy with Lhermitte's sign.

Williams, A C; Cullen, Michael; Haynes, I. G.

doi:10.1136/jnnp.49.11.1326-a

Cited by 6 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar latency period has been reported to occur in LS. In the majority of case reports, a latency period of 1-2.5 months is recognised [5,12,13,14,15,16,17,18]. Siegal et al [5], as part of a retrospective analysis of patients with cisplatin-induced peripheral neuropathy, reported 2 cases where patients treated with cisplatin for ovarian cancer developed LS 5.5 and 6 months post completion of therapy.…”

Section: Discussionmentioning

confidence: 99%

Lhermitte's Phenomenon and Platinum, Beware of Latency

O’Reilly

Ryan²,

MacEneaney³

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

SummaryBackground: Lhermitte's sign (LS) is characterized by electric shock-like sensations, spreading along the spine in a cervico-caudal direction and into the arms and legs. It is felt upon flexion of the neck and reflects a myelopathy resulting from damage to sensory axons at the dorsal columns of the cervical spinal cord. In patients with cancer, LS can occur due to direct tumour involvement of the spine or in relation to radiotherapy. Chemotherapy-related LS has only rarely been reported. Case Report: We present the case of a 44-year-old patient treated with platinum- and etoposide-based chemotherapy for metastatic seminoma, who subsequently developed severe disabling LS. The severity and duration of LS in this case exceeds prior reports. We review the literature on chemotherapy-related LS and discuss the practice implications. Conclusion: Neuropathy and LS related to cisplatin-based chemotherapy can result in significant adverse effects. Raised awareness of this complication could aid sub-phenotyping of the population most at risk and assist strategies to avert discomfort and disability post chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Lhermitte's Phenomenon and Platinum, Beware of Latency

O’Reilly

Ryan²,

MacEneaney³

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…A positive Lhermitte sign has been experienced by a number of patients and most authors have ascribed this phenomenon to involvement of posterior columns (Dewar et al, 1986;Williams et al, 1986).…”

Section: Neuropathic Syndromementioning

confidence: 99%

Neurological complications of chemotherapy to the peripheral nervous system

Postma

Heimans

2012

Handbook of Clinical Neurology

View full text Add to dashboard Cite

“…cluding tinnitus and high tone hearing loss, were reported in 10 patients. There were 2 cases of peripheral neuropathy severe enough to require discontinuation of vincristine and 2 patients developed Lhermitte's syndrome-following 5 and 6 courses of chemotherapy-which have been described separately (Williams et al, 1986). Troublesome mucositis with associated oral ulceration was reported in 6 patients.…”

Section: Time-yearsmentioning

confidence: 99%

Chemotherapy for Poor Risk Germ Cell Tumours An Independent Evaluation of the POM B/ACE Regime

Cullen

Harper

Woodroffe

et al. 1988

British Journal of Urology

View full text Add to dashboard Cite

We have evaluated the 7-drug, alternating, high-dose cisplatin regime for germ cell tumours, designated POMB/ACE, in 55 patients with advanced malignant teratomas and 5 patients with bulky metastatic seminomas. All of the latter and 5 of the teratoma patients had relapsed following radiotherapy, chemotherapy or both. The previously untreated teratoma patients included 13 whose tumours were extragonadal. The primary testicular tumour patients comprised 16 with large and 21 with very large volume metastases according to the Medical Research Council criteria. POMB/ACE is effective therapy for poor risk patients with germ cell tumours (including those with the most advanced disease, i.e. hepatic and cerebral metastases) and prolonged treatment after marker normality seems unnecessary. It is a complex regime with significant toxicity and cannot be recommended for the treatment of patients with germ cell tumours who have an excellent prognosis with simpler, shorter and less toxic treatment.

show abstract

Cisplatin neuropathy with Lhermitte's sign.

Cited by 6 publications

References 2 publications

Lhermitte's Phenomenon and Platinum, Beware of Latency

Lhermitte's Phenomenon and Platinum, Beware of Latency

Neurological complications of chemotherapy to the peripheral nervous system

Chemotherapy for Poor Risk Germ Cell Tumours An Independent Evaluation of the POM B/ACE Regime

Contact Info

Product

Resources

About